Analysts think CBIO stock price could increase by 28%
Jul 15, 2025, 11:25 AM
5.43%
What does CBIO do
GlycoMimetics, based in Rockville, Maryland, develops glycomimetic drugs to treat diseases influenced by carbohydrate biology, with candidates like Uproleselan for AML and GMI-1687 for subcutaneous use. The company went public in January 2014 and employs 35 people.
3 analysts think CBIO stock price will increase by 28.40%. The current median analyst target is $16.32 compared to a current stock price of $12.71. The lowest analysts target is $16.16 and the highest analyst target is $16.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.